JP2022535227A5 - - Google Patents

Info

Publication number
JP2022535227A5
JP2022535227A5 JP2021570943A JP2021570943A JP2022535227A5 JP 2022535227 A5 JP2022535227 A5 JP 2022535227A5 JP 2021570943 A JP2021570943 A JP 2021570943A JP 2021570943 A JP2021570943 A JP 2021570943A JP 2022535227 A5 JP2022535227 A5 JP 2022535227A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570943A
Other languages
English (en)
Japanese (ja)
Other versions
JP7655863B2 (ja
JP2022535227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035165 external-priority patent/WO2020243459A1/en
Publication of JP2022535227A publication Critical patent/JP2022535227A/ja
Publication of JP2022535227A5 publication Critical patent/JP2022535227A5/ja
Application granted granted Critical
Publication of JP7655863B2 publication Critical patent/JP7655863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570943A 2019-05-31 2020-05-29 Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体 Active JP7655863B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855495P 2019-05-31 2019-05-31
US62/855,495 2019-05-31
US202062990239P 2020-03-16 2020-03-16
US62/990,239 2020-03-16
PCT/US2020/035165 WO2020243459A1 (en) 2019-05-31 2020-05-29 Thiadiazolyl derivatives as dna polymerase theta inhibitors

Publications (3)

Publication Number Publication Date
JP2022535227A JP2022535227A (ja) 2022-08-05
JP2022535227A5 true JP2022535227A5 (https=) 2023-06-06
JP7655863B2 JP7655863B2 (ja) 2025-04-02

Family

ID=72179163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570943A Active JP7655863B2 (ja) 2019-05-31 2020-05-29 Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体

Country Status (10)

Country Link
US (2) US12509454B2 (https=)
EP (1) EP3976608B1 (https=)
JP (1) JP7655863B2 (https=)
CN (1) CN114127062A (https=)
AU (1) AU2020282768B2 (https=)
BR (1) BR112021024101A2 (https=)
CA (1) CA3141134A1 (https=)
ES (1) ES2968796T3 (https=)
TW (1) TW202110834A (https=)
WO (1) WO2020243459A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237595A (zh) * 2020-12-02 2022-10-01 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
MX2024003795A (es) * 2021-09-29 2024-06-03 Repare Therapeutics Inc Compuestos de n-(5-sustituido-[(1,3,4-tiadiazolil) o (tiazolil)])(sustituido)carboxamida y uso de estos para inhibir la polimerasa theta humana.
WO2023060573A1 (en) * 2021-10-15 2023-04-20 Beijing Danatlas Pharmaceutical Co., Ltd. Novel thiadiazolyl derivatives of dna polymerase theta inhibitors
WO2023067515A1 (en) * 2021-10-22 2023-04-27 Ideaya Biosciences, Inc. Thiadiazolyl compounds as dna polymerase theta inhibitors
EP4455129A4 (en) * 2021-12-30 2025-05-07 Shanghai Apeiron Therapeutics Company Limited Dna polymerase theta inhibitor and use thereof
CN118510778A (zh) * 2022-01-12 2024-08-16 百济神州有限公司 作为DNA聚合酶θ抑制剂的噻唑并吡啶基酰胺衍生物
US20250122221A1 (en) 2022-01-13 2025-04-17 Nanjing Zaiming Pharmaceutical Co., Ltd. Six-membered cyclothiazole compound and use thereof
TW202332442A (zh) 2022-01-31 2023-08-16 瑞士商瑞森製藥公司 ＰＯＬθ抑制劑
CN118871430A (zh) * 2022-03-10 2024-10-29 西藏海思科制药有限公司 DNA聚合酶 θ 抑制剂及其用途
WO2023202623A1 (zh) * 2022-04-20 2023-10-26 南京再明医药有限公司 Polq抑制剂化合物及其应用
CA3257870A1 (en) * 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
WO2023241322A1 (en) * 2022-06-16 2023-12-21 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
AU2023352129A1 (en) * 2022-09-29 2025-05-01 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
AU2023356904A1 (en) * 2022-10-03 2025-05-22 Recombination Therapeutics, Llc Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof
CN117946138A (zh) * 2022-10-28 2024-04-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其中间体、制备方法和应用
CN120077028A (zh) * 2022-11-10 2025-05-30 北京丹擎医药科技有限公司 噻二唑衍生物及其组合物和应用
WO2024099336A1 (en) * 2022-11-10 2024-05-16 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolyl derivatives, compositions and uses thereof
JP2025541823A (ja) * 2022-12-09 2025-12-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー４）、リミテッド Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用
WO2024149349A1 (zh) * 2023-01-14 2024-07-18 西藏海思科制药有限公司 靶向Polθ的化合物及其用途
KR20250153866A (ko) 2023-03-10 2025-10-27 브레이크포인트 테라퓨틱스 게엠베하 Dna 중합효소 세타 억제제
WO2024211836A2 (en) 2023-04-05 2024-10-10 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
WO2024213082A1 (en) * 2023-04-13 2024-10-17 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof
CN121729418A (zh) * 2023-05-05 2026-03-24 北京丹擎医药科技有限公司 环状衍生物及其组合物和应用
CN121712768A (zh) * 2023-05-30 2026-03-20 宁波新湾科技发展有限公司 噻唑基或噻二唑基酰胺衍生物及其用途
CN121399118A (zh) * 2023-06-02 2026-01-23 成都微芯药业有限公司 Polθ抑制剂及其制备方法和用途
WO2025011617A1 (zh) * 2023-07-12 2025-01-16 杭州圣域生物医药科技有限公司 并环杂芳环类化合物、其中间体、制备方法和应用
WO2025011603A1 (zh) * 2023-07-12 2025-01-16 南京再明医药有限公司 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途
AU2024295853A1 (en) * 2023-07-12 2026-02-12 Simcere Zaiming Pharmaceutical Co., Ltd. Salt of thiazolopyrazine compound or crystal thereof and use thereof
CN121772924A (zh) * 2023-07-12 2026-03-31 先声再明医药股份有限公司 Polq抑制剂化合物和抗癌治疗剂或者放射疗法的组合
CN121773109A (zh) * 2023-07-27 2026-03-31 北京丹擎医药科技有限公司 PolQ降解剂及其组合物和应用
WO2025036490A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种DNA聚合酶θ抑制剂及其用途
KR20260040065A (ko) * 2023-09-01 2026-03-23 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 바이아릴 고리계 화합물, 이의 중간체, 제조 방법 및 용도
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途
WO2025110780A1 (en) * 2023-11-24 2025-05-30 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025119195A1 (en) * 2023-12-08 2025-06-12 Danatlas Pharmaceuticals Co., Ltd. Combination of polq inhibitor and anti-cancer therapeutic agent
WO2025165092A1 (en) * 2024-01-30 2025-08-07 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025165094A1 (en) * 2024-01-30 2025-08-07 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
CN120829441A (zh) * 2024-04-24 2025-10-24 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
CN120829442A (zh) * 2024-04-24 2025-10-24 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
WO2025223483A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途
CN118515661B (zh) * 2024-07-22 2024-11-15 中国药科大学 一种靶向降解Polθ的化合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
EP3778600A1 (en) * 2014-03-20 2021-02-17 The Johns Hopkins University Compounds which inhibit rna polymerase, compositions including such compounds, and their use
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
USRE50319E1 (en) 2017-10-16 2025-03-04 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2022535227A5 (https=)
TWI891000B (zh) 三環parp1抑制劑及其用途
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
CN117980307A (zh) 取代的三环类化合物作为parp抑制剂及其应用
CN111320624B (zh) 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
AU2018312836B2 (en) Novel heterocyclic compounds as CDK8/19 inhibitors
CN119013279A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
AU2020270303A1 (en) Compound used as kinase inhibitor and application thereof
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
CN112457326B (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
CN116801882A (zh) 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法
AU2021290208B2 (en) Tricyclic compounds
KR20200078610A (ko) 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도
CN120535536A (zh) 稠合杂芳基类化合物、其制备方法及其在医药上的应用
WO2022017408A1 (zh) 芳胺类衍生物及其制备方法和医药用途
CN110407854B (zh) 新的四环化合物
CN116903613A (zh) 2-氧代喹唑啉并五元杂环衍生物、其制备方法及其应用
CN116888126B (zh) 一种酪蛋白激酶抑制剂的化合物
CN105712992A (zh) 作为cMet抑制剂的化合物及其制备方法和用途
CN119855817B (zh) 杂环炔基取代的酰胺衍生物、其制备方法及其应用
EA014312B1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
AU2022392348B2 (en) 15-pgdh inhibitor and use thereof
CN115215862A (zh) 嘧啶酮化合物及其用途
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂